RADIOGRAPHIC PROGRESSION-FREE SURVIVAL (RPFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN CHEMOTHERAPY-NAIVE METASTATIC CASTRATIONRESISTANT PROSTATE CANCER (MCRPC): A CORRELATION META-ANALYSIS

被引：0
|
作者：
Leung, L. [1 ]
Patel, M. [2 ]
Teitsson, S. [3 ]
Hofer, K. [1 ]
Qian, A. [1 ]
Kurt, M. [4 ]
机构：
[1] Evidinno Outcomes Res Inc, Vancouver, BC, Canada
[2] Bristol Myers Squibb, Lawrenceville, NJ USA
[3] Bristol Myers Squibb, Uxbridge, Middx, England
[4] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO55
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [31] Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review
    Shijie Yang
    Jing Zhan
    Xiequn Xu
    Endocrine, 2023, 82 : 491 - 497
  • [32] Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review
    Yang, Shijie
    Zhan, Jing
    Xu, Xiequn
    ENDOCRINE, 2023, 82 (03) : 491 - 497
  • [33] Progression-free survival and overall survival of pembrolizumab for patients with esophageal cancer: a meta-analysis
    Kurniawan, A.
    Wijovi, F.
    Angel, P.
    Priantono, D.
    Sari, C.
    Amelia, D. Astri Rivera
    Djatnika, D.
    Nasution, M. Arman
    Purlikasari, N. Prasasti
    Ariyanti, F.
    Wisman, B. Agustia
    Kurniawan, R.
    Sinurat, J.
    Ardian, A.
    Sugianto, G. Chandra Kirana
    Siregar, N. Novianti
    Dewi, N. Merlynda P.
    ANNALS OF ONCOLOGY, 2024, 35 : S1365 - S1365
  • [34] Progression-free survival and overall survival of pembrolizumab for patients with esophageal cancer: a meta-analysis
    Santoso, K. Aurelia
    Kosayuz, S.
    Atmaja, W. Surya
    Amalia, A. Irviani Ukhti
    Subroto, D. Ravinder Theodeus
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1365 - S1365
  • [35] Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS)
    Sokolova, Alexandra
    Graff, Julie N.
    Smith, Claire E.
    Beer, Tomasz M.
    Latour, Emile
    Grivas, Petros
    Schweizer, Michael Thomas
    Higano, Celestia S.
    Alumkal, Joshi J.
    Vuky, Jacqueline
    Yu, Evan Y.
    Cheng, Heather H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] APPLICATION OF PROGRESSION-FREE SURVIVAL AS SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN NICE REVIEWS OF ADVANCED BREAST CANCER DRUGS
    Zou, D.
    Sun, A.
    Musci, R.
    Milev, S.
    VALUE IN HEALTH, 2022, 25 (01) : S183 - S184
  • [37] Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer
    Hughes, Michael D.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2008, 17 (05) : 487 - 495
  • [38] Progression-free survival as a surrogate endpoint for hazard ratio and median overall survival in glioblastoma: A literature-based meta-analysis from 91 trials
    Han, K.
    Ren, M.
    Wick, W.
    Jin, J.
    Abrey, L.
    Das, A.
    Reardon, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S775 - S776
  • [39] Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
    Hamada, Tsuyoshi
    Nakai, Yousuke
    Isayama, Hiroyuki
    Yasunaga, Hideo
    Matsui, Hiroki
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Matsubara, Saburo
    Yamamoto, Natsuyo
    Tada, Minoru
    Koike, Kazuhiko
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 11 - 20
  • [40] Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials
    Li, Ling
    Pan, Zhanyu
    CLINICAL BREAST CANCER, 2018, 18 (01) : 63 - 70
12345